| Title |
Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, March 2018
|
| DOI | 10.1007/s00259-018-3992-5 |
| Pubmed ID | |
| Authors |
Garry Ceccon, Lazaros Lazaridis, Gabriele Stoffels, Marion Rapp, Manuel Weber, Tobias Blau, Phillip Lohmann, Sied Kebir, Ken Herrmann, Gereon R. Fink, Karl-Josef Langen, Martin Glas, Norbert Galldiks |
| Abstract |
We present our first clinical experience with O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes. We retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up. In all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI. FET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| United Kingdom | 2 | 22% |
| Australia | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 78% |
| Scientists | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 22% |
| Researcher | 3 | 11% |
| Student > Master | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Professor | 2 | 7% |
| Other | 5 | 19% |
| Unknown | 6 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 44% |
| Neuroscience | 3 | 11% |
| Computer Science | 1 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Physics and Astronomy | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2018.
All research outputs
#3,857,606
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#435
of 3,083 outputs
Outputs of similar age
#75,140
of 333,978 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#8
of 56 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.